Document Type
Article
Department
Haematology and Oncology, East Africa
Abstract
503 Phase I radioimmunotherapy (RIT) study of 90Y-CC49 monoclonal antibody (MAb) therapy in patients with advanced non-small cell lung cancer (NSCLC) × Close The Infona portal uses cookies, ie strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal.
Publication (Name of Journal)
Lung Cancer
DOI
https://doi.org/10.1016/S0169-5002(97)89883-2
Recommended Citation
Robert, F.,
Meredith, R.,
Khazaeli, M.,
Russell, C.,
Grizzle, W.,
Newsome, J.,
Saleh, M.
(1997). 503 Phase I radioimmunotherapy (RIT) study of 90Y-CC49 monoclonal antibody (MAb) therapy in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer, 18(1), 129.
Available at:
https://ecommons.aku.edu/eastafrica_fhs_mc_haematol_oncol/120
Comments
This work was published before the author joined Aga Khan University.